Gilead Sciences, led by CEO Daniel O'Day, maintains a robust HIV business foundation. Its collaboration with Galapagos underscores its commitment to innovation. Investors eyeing biotech stocks should monitor MRNA and GILD, as the company's forward-thinking approach positions it well for future growth and market leadership.